Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Several key aspects differentiate our library:
partner
Reaxense
upacc
P63261
UPID:
ACTG_HUMAN
Alternative names:
Gamma-actin
Alternative UPACC:
P63261; A8K7C2; P02571; P14104; P99022; Q5U032; Q96E67
Background:
Actin, cytoplasmic 2, also known as Gamma-actin, is a highly conserved protein pivotal in cell motility and expressed in all eukaryotic cells. Its role extends to maintaining the cell's structural integrity.
Therapeutic significance:
Gamma-actin's involvement in Deafness, autosomal dominant, 20, and Baraitser-Winter syndrome 2, highlights its potential in therapeutic strategies targeting sensorineural hearing loss and developmental disorders.